Skip to main content
    F

    Fractyl Health, Inc. Common Stock (GUTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.99
    +0.09 (+9.76%)

    Market Cap: $11.99M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Fractyl Health, Inc. Common Stock (GUTS) Financials: Revenue, Profit and Cash Flow

    Updated Aug 10, 2026. Financial statements from company filings, amounts in US dollars.

    Fractyl Health, Inc. Common Stock reported revenue of $0 for the fiscal year ended Sep 30, 2025, down 100.0% from the year before. That year, net income was -$140.95M, operating cash flow was -$90.33M and free cash flow was -$90.89M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$25.54M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Sep 2025, with an operating loss of $96.82M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$0-100.0%N/AN/AN/A
    Sep 2024$93.00K-22.5%46.2%-100571.0%-73864.5%
    Sep 2023$120.00KN/A35.8%-42363.3%-64242.5%
    Sep 2022$0N/AN/AN/AN/A
    Sep 2021$0N/AN/AN/AN/A
    Sep 2020$0N/AN/AN/AN/A
    Sep 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Sep 2019 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019
    Revenue$0$93.00K$120.00K$0$0$0N/A
    Cost of revenue$1.13M$50.00K$77.00K$452.00K$676.00K$770.00K$893.00K
    Gross profit-$1.13M$43.00K$43.00K-$452.00K-$676.00K-$770.00K-$893.00K
    Research and development$74.54M$70.47M$38.04M$34.35M$26.43M$22.43M$20.89M
    Operating income-$96.82M-$93.53M-$50.84M-$49.38M-$36.93M-$28.96M-$29.92M
    Net income-$140.95M-$68.69M-$77.09M-$46.45M-$38.73M-$30.48M-$30.59M
    EBITDAN/A-$68.02M-$50.55M-$46.00M-$36.62M-$28.19M-$29.03M
    Fiscal years ended Sep 2019 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$0$3.00K$14.00K$43.00K$33.00K$7.00K$36.00K
    Gross profit$0N/A-$279.00K-$290.00K-$270.00K-$290.00K$3.00K$7.00K$19.00K$14.00K-$33.00K-$73.00K
    Operating income-$19.10M-$20.82M-$23.28M-$22.69M-$26.08M-$24.76M-$25.21M-$23.79M-$22.98M-$21.54M-$12.98M-$13.87M
    Net income-$25.54M$9.22M-$43.73M-$45.60M-$27.89M-$23.73M-$24.97M-$23.17M-$17.23M-$3.32M-$19.18M-$15.75M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, cash and equivalents exceeded total debt of $35.69M by $45.85M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019
    Total assets$121.40M$108.08M$76.21M$60.96M$102.55M$34.76M$8.93M
    Current assets$87.58M$71.76M$35.65M$51.63M$96.39M$30.88M$6.78M
    Cash and equivalents$81.54M$67.46M$33.21M$49.27M$95.47M$29.11M$5.79M
    Total liabilities$111.94M$79.65M$401.27M$313.27M$311.87M$19.81M$152.93M
    Short-term debt$5.10M$4.96M$2.73M$1.25M$16.67M$7.17MN/A
    Long-term debt$30.59M$30.16M$55.15M$17.76MN/A$8.12M$14.90M
    Shareholder equity$9.46M$28.42M-$325.06M-$252.32M-$209.32M$14.95M-$144.00M
    Fiscal years ended Sep 2019 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$81.98M$99.39M$121.40M$114.27M$62.01M$83.04M$108.08M$126.92M$146.44M$163.52M$76.21M$56.78M
    Total liabilities$83.64M$78.01M$111.94M$117.45M$80.22M$76.67M$79.65M$76.60M$75.68M$79.34M$401.27M$363.96M
    Cash and equivalents$47.14M$63.17M$81.54M$77.66M$22.29M$42.11M$67.46M$84.66M$102.44M$121.44M$33.52M$44.50M
    Shareholder equity-$1.67M$21.38M$9.46M-$3.18M-$18.21M$6.38M$28.42M$50.32M$70.75M$84.18M-$325.06M-$307.18M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019
    Operating cash flow-$90.33M-$65.52M-$42.82M-$46.24M-$33.46M-$31.07M-$27.73M
    Capital expenditures$557.00K$1.76M$359.00K$56.00K$51.00K$2.00K$97.00K
    Free cash flow-$90.89M-$67.29M-$43.18M-$46.30M-$33.51M-$31.07M-$27.83M
    Investing cash flow-$557.00K-$1.76MN/A-$56.00K-$51.00K-$2.00K-$97.00K
    Financing cash flow$104.96M$101.23M$27.44M$4.35M$99.88M$54.39M$15.16M
    Fiscal years ended Sep 2019 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$15.90M-$22.48M-$21.34M-$22.71M-$21.20M-$25.08M-$17.03M-$18.04M-$18.74M-$11.71M-$10.60M-$11.02M
    Capital expenditures$0$0$3.00K$8.00K$98.00K$448.00K$233.00K$213.00K$260.00K$1.06M$136.00K$148.00K
    Free cash flow-$15.90M-$22.48M-$21.34M-$22.72M-$21.30M-$25.53M-$17.27M-$18.25M-$19.00M-$12.77M-$10.73M-$11.17M
    Last 12 quarters

    Frequently Asked Questions About GUTS

    What is Fractyl Health, Inc. Common Stock's annual revenue?

    Fractyl Health, Inc. Common Stock reported revenue of $0 for the fiscal year ended Sep 30, 2025.

    How fast is Fractyl Health, Inc. Common Stock's revenue growing?

    Revenue was down 100.0% for the fiscal year ended Sep 30, 2025 compared with the year before.

    Is Fractyl Health, Inc. Common Stock profitable?

    No. Fractyl Health, Inc. Common Stock reported net income of -$140.95M for the fiscal year ended Sep 30, 2025.

    How much free cash flow does GUTS generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of -$90.33M minus capital expenditures of $557.00K produced free cash flow of -$90.89M.

    How much debt does Fractyl Health, Inc. Common Stock have?

    The balance sheet dated Sep 30, 2025 reported long-term debt of $30.59M, short-term debt of $5.10M and cash and equivalents of $81.54M.